- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06303648
A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
April 14, 2024 updated by: Transcend Therapeutics
This is an open-label, single, ascending dose study evaluating the PK and safety of methylone in healthy subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ashley Lauritsch
- Phone Number: +1 (952) 250-7788
- Email: ashley@transcendtherapeutics.com
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- CMAX Clinical Research
-
Contact:
- Research Team
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Healthy adult male or female aged 25 to 55 inclusive
- Normal resting ECG
- Normal hematologic and hepatic function
- Normal renal function
Key Exclusion Criteria:
- Vital sign abnormalities
- Positive urine drug screen at screening and / or Day -1
- Current mental illness such as depression, anxiety disorder, schizophrenia or other psychotic disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
50 mg x 1 dose
|
Oral dose of methylone
|
Experimental: Cohort 2
100 mg x 1 dose
|
Oral dose of methylone
|
Experimental: Cohort 3
150 mg x 1 dose
|
Oral dose of methylone
|
Experimental: Cohort 4
200 mg x 1 dose
|
Oral dose of methylone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration for methylone
Time Frame: 48 hours following the dose
|
48 hours following the dose
|
AUC: Area under the plasma concentration-time curve for methylone
Time Frame: 48 hours following the dose
|
48 hours following the dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and frequency of adverse events
Time Frame: 10 days after the dose
|
10 days after the dose
|
Change overtime in Visual Analog Scales
Time Frame: 12 hours after the dose
|
12 hours after the dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2024
Primary Completion (Estimated)
May 4, 2024
Study Completion (Estimated)
May 11, 2024
Study Registration Dates
First Submitted
February 20, 2024
First Submitted That Met QC Criteria
March 4, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 14, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSND201-PK-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Disorder
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of NottinghamNottinghamshire Healthcare NHS Trust; Lincolnshire Partnership NHS Foundation...CompletedDomestic Violence | Trauma, Psychological | Post-Traumatic Stress Disorder in Children | Narrative Exposure Therapy | Post-Traumatic Stress Disorder in Adolescence | Post-Traumatic Stress Disorder ComplexUnited Kingdom
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States
Clinical Trials on Methylone
-
Transcend TherapeuticsNot yet recruitingPost Traumatic Stress DisorderAustralia
-
Transcend TherapeuticsEnrolling by invitationPost Traumatic Stress DisorderUnited Kingdom
-
Transcend TherapeuticsRecruitingPost Traumatic Stress DisorderUnited Kingdom, Ireland
-
Germans Trias i Pujol HospitalFundació Recerca Institut Germans Trias i Pujol; Istituto Superiore di SanitàActive, not recruitingHealthy Subjects | Substance UseSpain